Podcasts about tumors

Send us Fan MailWhat exactly is TP53, and why is it one of the most important genes to understand when talking about cancer?In this episode of Prevail Over Cancer, we take a closer look at TP53, often referred to as the “guardian of the genome.” We explore how this important tumor-suppressor gene helps regulate cell growth, repair damaged DNA, and prevent abnormal cells from continuing to multiply.We'll discuss what happens when TP53 becomes mutated or stops functioning properly, why TP53 mutations are found in many different types of cancer, and why understanding this gene can provide valuable insight into the biology of cancer.In this episode, we explore:• What TP53 is and how it works• Why TP53 is considered a tumor-suppressor gene• The relationship between TP53 mutations and cancer• How TP53 helps control damaged or abnormal cells• Why TP53 is important in understanding cancer biologyKnowledge is an important part of your cancer-fighting journey. Listen, learn, and continue to Prevail Over Cancer.This Episode is brought to you by Ultra Botanica, our top choice when it comes to Supplements to assist your journey on Preventing, Beating and Prevailing Over Cancer.  Our Listeners get an additional 20% off their complete orders or subscriptions.https://ultrabotanica.com/discount/POC20Give Jeff Lopes a Follow on Instagram - https://www.instagram.com/jefflopes/ Check out Keith Bishop on on Instagram https://www.instagram.com/prevailovercancerCheck out a incredible Blog on Cancerhttps://www.prevailovercancer.com/blogIf you or a Loved one have been recently diagnosed or are battling through this metabolic disease please reach out to Keith Bishop.  Keith has helped thousands through there journey.Visit - https://www.prevailovercancer.com#PrevailOverCancer #CancerPodcast #TP53 #TumorSuppressor #CancerResearch #CancerAwareness #CancerEducation #CancerJourney #CancerPrevention #Genetics #DNA #CancerSupport #Episode289Ultra BotanicaOur Listeners Get 20% off there Entire order & Monthly SubscriptionsSupport the show

In this episode of SurgOnc Today, breast surgical oncologists explore circulating tumor DNA (ctDNA) in early-stage breast cancer and what breast surgeons need to know about this rapidly evolving biomarker. The panel explains what ctDNA is, how it is detected, and its emerging role in identifying molecular residual disease and assessing treatment response. They review the current evidence for ctDNA testing during neoadjuvant therapy, after surgery, and during surveillance, while highlighting important limitations in using ctDNA to guide treatment and surgical decision-making. The conversation also addresses how to counsel patients who request testing and what evidence is still needed before ctDNA can become part of routine breast cancer care.

You can eat clean, do everything right, and still miss a brain tumor growing for years. Taylor Dukes found hers on a routine full-body scan, then shrank it in half before surgery using metabolic ketosis, methylene blue, and red light. Gary sits down with Taylor, Dr. Will Cole, and Dr. Josh Axe to break down what standard labs miss: hidden parasites, mold toxicity, and stealth infections quietly overloading the immune system. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Connect with Taylor Dukes: Website: https://bit.ly/4byxTS5  Instagram: https://bit.ly/3Rii1cS Connect with Dr. Will Cole: Website:https://bit.ly/4iurxF0  Instagram:https://bit.ly/3GlSihK     Connect with Dr. Josh Axe: Website: https://bit.ly/4mEUwIc  Instagram: https://bit.ly/42ULi3s  Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: “ULTIMATE20” FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: “ULTIMATE10” FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp CYMBIOTIKA: “BRECKACYM30” FOR 30% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 01:14 - Full-body scan finds a brain tumor 04:35 - Ketosis, methylene blue, and red light 07:06 - Toxoplasma gondii parasite found in blood 07:41 - Tumor shrinks in half before surgery 09:22 - Recovery with no chemo or radiation 11:32 - Symptoms conventional labs miss 12:30 - HLA genes and biotoxin sensitivity 14:55 - Glyphosate and microplastics in your body 15:24 - Mold exposure and Epstein-Barr reactivation 19:15 - Gut healing, sauna, and binders 22:05 - Why you strengthen before you kill 26:36 - Black walnut and wormwood for parasites 28:06 - Family Lyme disease and long COVID 30:08 - Herbs and therapy for fighting Lyme 31:05 - Recap: three paths to the same truth Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

Cancer cells do not grow in isolation. Their ability to survive and form tumors depends partly on how they interact with immune cells in the surrounding tumor microenvironment. Melanoma is particularly responsive to immune-based mechanisms, making it important to understand the molecular processes that allow melanoma cells to limit or escape antitumor immune responses. A research paper published in Volume 17 of Oncotarget, titled “DHHC3 interferes with antitumor immunity in melanoma cells,” investigated the role of the protein acyltransferase DHHC3 in melanoma growth, oxidative stress, cellular senescence, and antitumor immunity. Why Study DHHC3 in Melanoma? DHHC3 is one of 23 members of the DHHC family of protein acyltransferases. These enzymes modify proteins through a process known as palmitoylation, which can influence where proteins are located within cells and how they function. Previous research from the investigators showed that DHHC3 palmitoylates numerous antioxidant and redox-regulatory proteins, providing a mechanism through which it helps control intracellular oxidative stress. Higher DHHC3 expression has also been associated with poorer survival across several cancer types, while DHHC3 ablation has previously been shown to reduce breast tumor growth. However, an important question remained unresolved: does eliminating DHHC3 suppress tumors because of changes occurring directly within cancer cells, or because those changes allow the immune system to attack the tumor more effectively? Full blog post - https://www.oncotarget.org/2026/09/23/dhhc3-helps-melanoma-tumors-evade-antitumor-immunity/ DOI - https://doi.org/10.18632/oncotarget.28880 Correspondence to - Martin E. Hemler - martin_hemler@dfci.harvard.edu, and Chandan Sharma - csharma@mgh.harvard.edu Abstract video - https://www.youtube.com/watch?v=QQhP2VhzKSE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28880 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of Curing with Sound, we speak with Daniel Sheeran, MD, an interventional radiologist at the University of Virginia, about histotripsy, a form of focused ultrasound that mechanically destroys targeted tissue without incisions or heat. In 2023, the US Food and Drug Administration cleared the HistoSonics Edison™ histotripsy system for the noninvasive destruction of liver tumors. Dr. Sheeran, who performed UVA's first histotripsy procedure in June 2025, explains how the technology works and shares insights from his experience integrating this new treatment option into clinical practice. Dr. Sheeran offers a closer look at the role of histotripsy in the broader treatment landscape for liver tumors and the questions researchers are still working to answer, including its impact on long-term patient outcomes. He also emphasizes the importance of understanding all available treatment options when making decisions about cancer care.  Discussion highlights: A New Noninvasive Option for Liver Tumors: Learn how histotripsy uses focused ultrasound to generate microscopic bubbles that mechanically destroy targeted tissue without incisions or heat—and how the FDA-authorized technology is being incorporated into clinical care.  From Innovation to Patient Impact: Explore why successfully destroying a tumor is only one measure of treatment impact—and why ongoing research is needed to understand histotripsy's effects on long-term outcomes, quality of life, and survival.  EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Desetletja raziskav in zdravljenja rakavih obolenj, ki ostajajo ena najusodnejših bolezni v razvitem svetu, so ob številnih uspehih nazorno pokazala tudi to, s kako zelo kompleksnimi boleznimi imamo pravzaprav opravka. Že sami tumorji niso preproste gmote podivjanih celic, ampak zapleteno omrežje različnih celic, med katerimi poleg tumorskih, rakavih celic najdemo tudi netumorske. Zaradi kompleksnosti teh tvorb se vse pogosteje govori kar o tumorskih ekosistemih. Ti so, kot kažejo raziskave, sposobni zelo sofisticirane komunikacije z okoliškim, zdravim tkivom in si na različne načine utirajo poti za nadaljnje širjenje po telesu.Prav ta komunikacija je vse bolj pod drobnogledom raziskovalcev, kajti prav tu se utegnejo skrivati odgovori, kako se lotiti tistih rakov, ki se obstoječim terapijam najučinkoviteje izmikajo. Med temi je zagotovo tudi glioblastom, najpogostejši in tudi najagresivnejši možganski tumor. Ta je tudi v središču raziskav doc. dr. Barbare Breznik, vodje raziskav biologije raka na Nacionalnem inštitutu za biologijo, ki je bila tokrat gostja v oddaji Podobe znanja.Gre za ponovitev oddaje.

We cover - Kentucky Tumor Buck, Broadheads, arrows, blood trails, a super fun upcoming pronghorn hunt, and the Timber Ninja Kunai and Mini Kunai platform. Hope ya'll enjoy! @wheelsupoutdoors to find Chris.https://elevatedresearchdesigns.com/https://www.codeofsilence.com/https://www.tactacam.com/hunt-camerashttps://map.spartanforge.ai/https://vortexoptics.com/https://altraarrows.com/https://elitearchery.com/

https://soundcloud.com/rene-de-paula-jr/novas-esperancas-para-o-cancer This Woman Cured Her Cancer with an Insane Method https://youtu.be/0NY2gAftzJE?si=PliIACmND2B_Aqn3 ‘Smart' Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy https://www.wired.com/story/smart-nanoparticles-deliver-mrna-directly-to-tumors-in-new-cancer-therapy/ What if ‘consciousness' isn't real? https://www.scientificamerican.com/article/what-if-consciousness-isnt-real/ The Dark Side of Mindfulness https://www.theatlantic.com/ideas/2026/09/meditation-willoughby-britton-downsides/688474/?gift=vvo9TFcXgFbQlwck3s_la8QEPWFgbKgzlQYEiOI39g4&utm_source=copy-link&utm_medium=social&utm_campaign=share  The Dark Side of Meditation https://youtu.be/kN8OLF-MocU?si=XwZSdJaqdTDEOSsD a app do radinho!!!    http://radinhodepilha.com/radinho  canal do radinho no telegram:   http://t.me/radinhodepilha meu perfil no Threads: https://www.threads.net/@renedepaulajr meu perfil no BlueSky https://bsky.app/profile/renedepaula.bsky.social meu twitter http://twitter.com/renedepaula aqui está o link para a caneca no Colab55:  https://www.colab55.com/@rene/mugs/caneca-rarissima  para xs raríssimxs internacionais, aqui está nossa caneca no Zazzle: https://www.zazzle.com/radinhos_anniversary_mug-168129613992374138 minha lojinha no Colab55 (posters, camisetas, adesivos, sacolas):  http://bit.ly/renecolab meu livro novo na lojinha!  blue notes https://www.ko-fi.com/s/550d7d5e22 meu livro solo https://www.ko-fi.com/s/0f990d61c7  o adesivo do radinho!!!   http://bit.ly/rarissimos  minha lojinha no ko-fi: https://ko-fi.com/renedepaula/shop muito obrigado pelos cafés!!!  http://ko-fi.com/renedepaula

Send us Fan MailMorning Prayers (Praise; Cleanse us; Overcoming Discouragement; CNS Tumors; Marriages; Each Other; Thanks)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

Envíame un mensajeDominic Auricchio tenía apenas 10 años cuando los médicos descubrieron una gran masa en su cerebro. Ante la incertidumbre y los riesgos de una posible intervención, Dominic y su familia se refugiaron en la oración. Dominic asegura que recibió la visita de la Santísima Virgen María y que Ella le transmitió un mensaje de esperanza: todo estaría bien. Posteriormente, los estudios médicos mostraron una reducción considerable del tumor.¿Estamos ante un verdadero milagro? ¿Puede considerarse auténtica esta supuesta aparición? ¿Qué tendría que ocurrir para que la Iglesia Católica investigara y eventualmente reconociera un acontecimiento de esta naturaleza?En este programa analizamos el testimonio de Dominic, lo ocurrido con su tumor y, sobre todo, el proceso de discernimiento que utiliza la Iglesia ante supuestos milagros y apariciones. Hasta el momento, la Iglesia no ha declarado oficialmente que la experiencia de Dominic sea una aparición sobrenatural ni un milagro. Por eso distinguiremos entre el testimonio del joven, los hechos médicos conocidos y lo que todavía requiere investigación y discernimiento.Una historia extraordinaria de enfermedad, oración, esperanza y confianza en Dios.Peregrinación a España y PortugalDel 9 al 21 de noviembre de 2026, te invitamos a una profunda peregrinación a España y Portugal.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showYouTubeFacebookTelegramInstagramTik TokTwitter

A listener with a breast tumor sitting just under the skin has already tried ozonated olive oil salve and calendula creams and wants to know what else can go on it. Dr. Lodi's answer, the longest of the show by a wide margin, is Lugol's liquid iodine with DMSO to carry it in.He takes Lugol's apart into potassium iodide and molecular iodine, two iodine atoms bound together, and says the molecular iodine does the work, by the same mechanism that made the iodine a mother once dabbed on a cut worth using. He argues it also shifts estrogen toward metabolites that do not stimulate growth. He says the DMSO goes on clean skin to carry the iodine in, and he warns it can irritate the skin enough that daily use may not be possible. He is plain about the limit: it only applies where a growth is near the surface and "it's reachable", not in the spleen or pancreas. He raises radiofrequency ablation, cryotherapy and histotripsy, then says none of it is the answer on its own, because if the toxins and the immune imbalance are left alone the growth comes back. Underneath it is his view of healing: "healing is not a transitive verb. It's not something you do. It's something that happens."The other questions cover a pituitary macroadenoma found on a scan taken for hearing loss in both ears, where he says an adenoma does not spread but that surgery is almost always the route; an inflamed bladder where a urine test found no bacteria, which he says is most likely the antibiotic already taken, and where he asks for a long juice cleanse; prostate cancer that has already spread, where he goes to bone; a rash on the neck, where he wants the real aloe vera plant, not a store product; two small benign liver lesions; autism and iodine; hot flashes on bioidentical hormones; and osteoporosis of the spine. Partway through, the camera and microphone fail and he sends everyone to Instagram while he restarts. He runs out of time on honey, dates and fruit and holds it to the following week.Covered in this episodeIodine and DMSO on a tumor near the skinPituitary macroadenoma and hearing loss in both earsAn inflamed bladder where no bacteria were foundProstate cancer that has already spreadA major rash on the neck and fresh aloe veraWhether skin growths are the same as any otherWhether a breast tumor is really hormone drivenTwo small benign liver lesionsAutism and iodineHot flashes on bioidentical hormonesOsteoporosis of the spineSend us Fan Mail Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Support the showThis episode is the audio of Dr. Lodi's free Sunday Night Live, where he answers health and cancer questions sent in by viewers.He goes live every Sunday at 8pm New York time on YouTube, Facebook, Instagram and TikTok.Send your question in before the show:https://drlodi.com/contact-dr-lodi/livestream-qa/Follow Dr. LodiYouTube: youtube.com/@DrThomasLodiFacebook: facebook.com/DrThomasLodiInstagram: instagram.com/drthomaslodiTikTok: tiktok.com/@drthomaslodimd

HER2 has long been synonymous with breast cancer, but a growing body of evidence shows it's expressed, at some level, across nearly every solid tumor type. In this episode of Targeted Talks, host Sabrina Serani sits down with Dr Aditya Shreenivas (City of Hope National Medical Center) and Dr Razelle Kurzrock (Medical College of Wisconsin Cancer Center) to unpack their new real-world analysis, published in ESMO Open, using data made available by Caris Life Sciences, examining HER2 immunohistochemistry (IHC) expression and ERBB2 alterations across more than 200,000 tumors.The conversation traces how HER2 evolved from a breast cancer biomarker to a tumor-agnostic target, following the accelerated approval of fam-trastuzumab deruxtecan (T-DXd; Enhertu) for HER2 IHC 3+ solid tumors. Drs Shreenivas and Kurzrock walk through the study's key findings: how ERBB2 amplification and mutation status each relate to HER2 IHC expression, why that relationship is more complex—and more clinically important—for mutations than for amplifications, and what it means when the biomarkers disagree. They also dig into overall survival data showing that the prognostic benefit of high HER2 expression is largely concentrated in breast and gastric cancers, where HER2-targeted therapies are already standard of care, vs rarer tumor types like salivary gland and endometrial cancer, where the picture looks different.Listeners will come away with a clearer sense of why HER2 should be treated as a continuous variable rather than a binary positive/negative result, why routine HER2 IHC testing matters for every patient with unresectable or metastatic disease, and where the open questions remain, including discordant cases where amplification and IHC don't line up.A must-listen for oncologists, pathologists, and researchers working across breast, GI, gynecologic, and rare solid tumors who want a real-world, pan-cancer view of the evolving HER2 landscape.

(00:00:00) 233: Docs Answer Listener Questions: Global Edition III (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pet Supplements (00:01:05) Global Reach of Itchy and Bitchy (00:03:14) Addressing Listener Questions (00:06:26) Cyclospora and Food Safety (00:09:51) Tick-Borne Illnesses and Prevention (00:12:35) Break Announcement (00:12:53) Creatine Supplements: Benefits and Risks (00:15:51) Raw Diets and Food Safety for Pets (00:17:57) Break Announcement Listeners from around the globe send in questions for the Docs to give their best answers: most common countries for listenership, dog skin cancer, lumps and bumps, cardiac questions, diets and food science, cyclospora, toxins, vital monitoring and wearables, and more ....Become a supporter of this podcast: https://www.spreaker.com/podcast/itchy-and-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

Dr. Roberto Diaz, a neurosurgeon and Assistant Professor of Neurology and Neurosurgery at McGill University who specializes in the neurosurgical treatment of brain tumors, joined Aaron Rand

+++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/bushido_podcast +++ Es geht ums Geld in dieser Folge - denn der Urlaub hat richtig viel davon geschluckt - und trotzdem lief er nicht so wie erhofft. Deswegen haben Anna-Maria und Anis auch Konsequenzen gezogen und sich nicht nur nach einem Haus am Tegernsee umgesehen, sondern auch ein Haushaltskonto angeschafft, um wieder einen Überblick über die Ausgaben zu bekommen. Und auch die Kinder haben jetzt eigene Konten und Taschengeld, damit sie lernen mit ihren Finanzen umzugehen. Am Ende ist aber klar: alles Geld der Welt ist nichts wert, wenn Du nicht gesund bist. Das hat Anis die letzten Tage wieder erleben dürfen, als es um die Entfernung seines Tumors ging und die Frage: ist er wirklich gutartig? Dieser Podcast wird vermarktet von Julep Media: sales@julep.de Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, melden Sie sich hier: datenschutz@julep.de

Comedian and TigerBelly favorite Adam Ray joins the Slept Kingdom. We chat the Korean spa sitcom, baby name pitches, the blind Antarctica cruise, tumor coyote, Bobby's wedding speech, and who we'd eat first on a deserted island.Go to http://kalshi.com/r/TIGERBELLY to check out Kalshi. This link will apply code TIGERBELLY to unlock your rewards, Listeners can trade $25 and receive $25 with our exclusive offerDownload Cash App today and make your money work for you. Visit our link in bio.For simple, online access to personalized and affordable care for Hair Loss, Weight Loss, and more, visit www.hims.com/BELLY See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY – September 1, 2026 – A new #review was published in Volume 17 of Oncotarget on August 28, 2026, titled “Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational challenges.” The review was led by first author Omkar Dhaygude, who is affiliated with Johns Hopkins University. Corresponding authors Franck Housseau and John Michel are affiliated with Johns Hopkins University, with Housseau also affiliated with the Cancer Research Center of Lille in France. Extracellular vesicles (EVs) are membrane-enclosed particles released by cells that transport proteins, lipids, nucleic acids, metabolites, and other molecular cargo. In cancer, tumor-derived extracellular vesicles (TEVs) can influence the tumor microenvironment and distant tissues by promoting processes such as angiogenesis, extracellular matrix remodeling, inflammatory signaling, immune evasion, and stromal reprogramming. Of particular interest is the role of TEVs in establishing premetastatic niches—biological environments in distant organs that become permissive to metastatic cells before overt tumors are detectable. TEVs can carry organ-specific molecular signals, and their surface molecules may influence which tissues they reach. For example, previous experimental research has linked the integrins α6β4 and α6β1 with lung tropism, providing a biological rationale for using TEVs to direct imaging probes toward metastasis-prone organs. This possibility could address an important limitation of conventional cancer imaging. Computed tomography and other anatomical methods are designed primarily to detect established structural lesions, whereas premetastatic niches are characterized by earlier molecular and microenvironmental alterations. The authors therefore examine whether TEV-associated imaging could provide information about metastatic conditioning before conventional imaging can identify overt metastatic lesions. Full press release - https://www.oncotarget.com/news/pr/tumor-derived-extracellular-vesicles-show-promise-for-earlier-detection-of-metastatic-risk/ DOI - https://doi.org/10.18632/oncotarget.28916 Correspondence to - Franck Housseau - fhousse1@jhmi.edu, and John Michel - jmiche14@jhmi.edu Abstract video - https://www.youtube.com/watch?v=0zygNvj4_YY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28916 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, lung metastases, cancer imaging, theranostic, premetastatic niches, extra-cellular vesicles To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Shengjie Li, Jiazhen Cao, Jun Ren, Kun Chen, Jianing Wu, Yingzhu Li, Yunxiao Song, Chengxun Li, Wenjun Cao, Ming Guan. Tumor-Derived HAVCR1 As a Reliable Fluid Biomarker for the Diagnosis of CNS Lymphoma. Clin Chem 2026; 72(8): 880–92.  https://doi.org/10.1093/clinchem/hvag036

BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.” The editorial was led by first and corresponding author Bhartendra Sharma from Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India, along with co-authors Sukhbir Kaur, Vikas Sharma and Sanjay Soni. Tumor-infiltrating lymphocyte (TIL) therapy is a form of adoptive cellular therapy that uses immune cells naturally present within tumors to attack cancer. Unlike chimeric antigen receptor (CAR) T-cell therapy, which genetically modifies a patient's T cells to recognize specific tumor antigens and has achieved its greatest success in hematological malignancies, TIL therapy has shown potential in several types of solid tumors. The approach has a history spanning more than four decades. Steven Rosenberg first isolated TILs from a mouse tumor in 1982, and subsequent experiments demonstrated antitumor effects when TILs were combined with cyclophosphamide and interleukin-2 (IL-2). In 1988, Rosenberg and colleagues reported favorable clinical outcomes after administering TIL therapy to patients with metastatic melanoma. Full press release - https://www.oncotarget.com/news/pr/tumor-infiltrating-lymphocyte-therapy-offers-a-promising-approach-for-treating-solid-tumors/ DOI - https://doi.org/10.18632/oncotarget.28883 Correspondence to - Bhartendra Sharma - bhartendrasharma@mgumst.org Intro video - https://www.youtube.com/watch?v=QAr_R4WCJfk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28883 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, tumor infiltrating lymphocytes, solid tumors, adoptive cellular therapy, immunotherapy To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

[include file=get-in-itunes.html] This show is about an hour and forty five minutes long! We hope you enjoyed it. It’s so interesting because Kate and I get talking and before we know it an entire hour has gone by. Sometimes we don’t even introduce ourselves on the Free For All Friday shows until 20 minutes in […] The post Dream Interpretations, Tumors In Kate’s Liver, Worms, My Near Death Experience, Listener Questions & More! appeared first on Extreme Health Radio.

BUFFALO, NY – August 28, 2026 – A new #research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.” The study was led by first author Kelly Crane from the Department of Urology at SUNY Upstate Medical University. The corresponding author is K. R. Seetharam Bhat, who is affiliated with the Department of Urology at SUNY Upstate Medical University and Upstate Urology at MVHS. KRAS is one of the most extensively studied oncogenes in cancer, and the G12C variant has become clinically important following the development of mutation-specific inhibitors. Although KRAS G12C-targeted therapy is established in other malignancies, its frequency and genomic characteristics in genitourinary cancers have remained less well defined. To address this gap, the researchers performed comprehensive genomic profiling of 13,654 tumor specimens from patients with metastatic disease, including 1,453 renal clear cell carcinomas, 3,879 urothelial bladder carcinomas, and 8,322 prostate acinar adenocarcinomas. Tumor mutational burden, microsatellite instability, and PD-L1 expression were also evaluated. Across the full cohort, KRAS alterations were detected in 367 tumors, or 2.7%, while KRAS G12C was identified in only 25 tumors, representing approximately 0.2% of all specimens. No G12C variants were found among the renal clear cell carcinomas. In urothelial bladder carcinoma, 24 of 202 KRAS-altered tumors, or 12%, carried G12C, while only one of 158 KRAS-altered prostate tumors contained the variant. Full press release - https://www.oncotarget.com/news/pr/kras-g12c-mutation-identified-as-a-rare-potential-target-in-genitourinary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28912 Correspondence to - K. R. Seetharam Bhat - bhatkuls@upstate.edu Abstract video - https://www.youtube.com/watch?v=me9HXtnDmp4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28912 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, KRAS mutation, genitourinary malignancy, precision medicine, emerging target To learn more about the journal, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Today I finally get to sit down properly with the incredible Karen Mills, Hall of Famer, Grand Ole Opry veteran, and one of the funniest women touring today. She came back to do this twice because we lost the audio the first time. That's the kind of woman she is.We talk about cancer, car accidents, the Ryman, and why comedy is the only medicine that matters. ⸻⏱️ Episode Timeline & Highlights[00:40] – Basketball, limo driving, and finding comedy [04:21] – Karen's record-breaking stats at UT Chattanooga [12:26] – From open mic to full-time in three years [23:19] – Standing in the circle at the Grand Ole Opry [29:15] – The parking lot Nell incident and 15 very upset fans [38:07] – Three travel must-haves (the foam roller always wins) [45:35] – Cancer, a car accident, and being hard to kill [47:49] – "Humor for the Tumor": The comedy community shows up [49:37] – Sneaking my brother's ashes into the Ryman [53:14] – Memoir "Hard to Kill" coming summer 2027⸻Links & Resources Mentioned• Follow Karen on Instagram & TikTok: @karenmillscomedy • Karen on Facebook: @karenmillscomedian • Karen's website: karenmills.com • Dry Bar Special & Natty Etsy Showcase – Available now at karenmills.komi.io • Sirius XM – Catch Karen regularly on the comedy channels⸻Closing ThoughtsKaren Mills is proof that resilience and humor can get you through anything. Like, subscribe, and share with someone who needs a laugh today. See you next time!#suzichicago #karenmills #hardtokill #grandoleopry #womenincomedy #comedypodcast #cleancomedy #cancersurvivor #leannemorgan #kathleenmadigan #standupcomedy #podcastinterview

In this episode, Dr. Mike Hart sits down with Dr. Leigh Erin Connealy for a wide-ranging conversation on cancer prevention and the factors she believes influence long-term health. Dr. Connealy shares her perspective on why cancer should be approached as a whole-body problem, exploring the roles of nutrition, metabolic health, environmental toxins, sleep, stress, hormones, and mitochondrial function. They also discuss fasting and ketogenic diets, cancer screening, GLP-1 medications, aspirin, peptides, medicinal mushrooms, IV vitamin C, and other integrative approaches, along with Dr. Connealy's concerns about conventional screening and treatment practices. Throughout the conversation, she emphasizes individualized care and looking beyond a diagnosis to understand the broader conditions affecting each patient.   Dr. Leigh Erin Connealy is a medical doctor with four decades of experience who takes a prevention-focused, whole-person approach to health, longevity, and complex chronic disease. Her work spans human optimization through advanced conditions including cancer, dementia, autoimmune disease, and Parkinson's, with an emphasis on identifying and addressing factors that may interfere with the body's ability to function optimally. Her approach was shaped in part by her own health journey after learning that she had been exposed before birth to DES (diethylstilbestrol), which led her to undergo ongoing evaluations at MD Anderson and explore medicine beyond conventional symptom-based care. Over her career, she has incorporated individualized laboratory assessment, natural hormones, nutrition, peptides, and other integrative strategies while emphasizing what she describes as "creating health" rather than simply treating a diagnosis.    [The Cancer Revolution] — Leigh Erin Connealy, MD / Hachette Book Group https://www.hachettebookgroup.com/titles/leigh-erin-connealy/the-cancer-revolution/9780306836688/ [Be Perfectly Healthy] — Leigh Erin Connealy, MD / Perfectly Healthy https://perfectlyhealthy.com/products/be-perfectly-healthy-1 [Celluverse Podcast] — Dr. Leigh Erin Connealy, Alannah Connealy & Jess Donovan https://podcasts.apple.com/us/podcast/celluverse/id1836455844 [Dr. Leigh Erin Connealy Instagram — @connealymd] — Leigh Erin Connealy, MD https://www.instagram.com/connealymd/ [Cologuard Plus] — Exact Sciences Corporation https://www.cologuard.com/resources [QTI Breast Acoustic CT Scanner] — QT Imaging Holdings, Inc. https://www.qtimaging.com/breast-acoustic-ct-scanner/ [UT MD Anderson Cancer Center] — The University of Texas MD Anderson Cancer Center https://www.mdanderson.org/ [Eminence Organic Skin Care — Sun Care] — Eminence Organic Skin Care https://eminenceorganics.com/us/face/sun-care [Primally Pure Sunscreen] — Primally Pure https://primallypure.com/pages/sunscreen [COOLA Sunscreen] — COOLA https://coola.com/collections/sunscreen   Show Notes 00:00 Welcome to the Hart2Heart Podcast 01:07 Root Cause Medicine 02:29 Is Cancer Preventable 05:42 Biggest Risk Factors 09:51 Toxins And Detox Testing 12:26 Sweating And Detox Baths 00:00 Doctors Not Listening 16:58 Does Sugar Feed Cancer 22:37 Fasting And Keto Strategies 26:05 Mushrooms And Supplements 27:21 Thiamine And Nutrient Gaps 29:35 Hormones And Cancer Risk 35:42 Complete Hormone Panels 38:02 GLP-1s and Cancer Risk 39:18 Daily Aspirin Debate 41:12 Peptides to Avoid 43:20 Russian Peptides Cycling 45:43 Non Toxic Sunscreen Choices 47:14 Deodorants and Aluminum 48:18 AirPods and Brain Health 50:26 Cancer Screening Strategy 54:30 Breast Imaging Options 56:05 Biopsy Spread Concerns 58:09 Why Medicine Misses Prevention 01:01:55 Personal DES Cancer Journey 01:03:10 IV Vitamin C for Cancer 01:04:26 Where to Follow and Book   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

August 21, 2026In this episode, Scott, Mark, and Dr. Ray Painter revisit the coding and documentation requirements for cystoscopic bladder tumor treatment. They discuss why tumor size—not the size of the resection bed—drives code selection, how multiple tumors are handled, and why documenting the exact bladder location is increasingly important for diagnosis coding. The team also explains when to use malignant, uncertain, or unspecified neoplasm codes, why you should code based on what is known at the time of the procedure, and when a same-day bladder instillation may or may not be separately billable. The key takeaway: bladder tumor coding is highly detail-dependent, and accurate documentation of size, location, diagnosis, and any separately performed services is essential to support reimbursement PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

The CIA declassified document CIA-RDP80-00809A000600 on Sep 14th, 2011 in the 1951 Russian research findings on the relationships between parasites and cancer tumors. I read the document for those interested and update on how Moringa powder and a dermatologist hair product is working to address my perimenopause symptoms.

Amy’s son is dealing with an injury causing him tons of pain and needs our help. Eddie has great news on his mom’s recovery from having a tumor removed. Lunchbox got his 4th PRP shot or at least we think it was a PRP shot. We investigate what was put into his body. Bobby talks about having a busy but good day yesterday with his friend Brett Eldredge. Raymundo has an update on the Pop-A-Shot machine delivery.See omnystudio.com/listener for privacy information.

Broadcast from KSQD, Santa Cruz on 8-13-2026: Dr. Dawn opens by reading an anatomy student's elegy to a body donor, reflecting on how modern medical education has moved away from full cadaver dissection toward pre-dissected specimens and models—and what she believes has been lost in that transition. Dr. Dawn dissects how hospital consolidation has become the primary driver of runaway U.S. healthcare costs. She contrasts a $16,000 knee replacement at Catawba Valley Medical Center with a $40,000 procedure for the same Blue Cross Blue Shield plan an hour away at Asheville's Mission Hospital—a facility formed by the 1998 merger of the town's two acute-care hospitals and later acquired by HCA in 2018. Mission now charges 333% of Medicare rates (versus a 280% benchmark), and state inspectors have issued three "immediate jeopardy" findings since HCA's takeover, consistent with academic findings that hospital care quality drops when competition disappears. She notes that CMS-required price disclosures since 2021 finally make this transparent, and calls for regulatory prevention of hospital mergers—especially not-for-profit to for-profit conversions—in single or two-hospital markets. Dr. Dawn analyzes the 3.1% year-over-year drop in prescription drug prices reported through July—the sharpest decline since 1963. She attributes most of it to Biden's 2022 Inflation Reduction Act, which partially rescinded George W. Bush-era Medicare Part D restrictions that had statutorily prohibited price negotiation, saving taxpayers roughly $6 billion in the first six months of implementation. Additional contributors include GLP-1 compounding competition, blockbuster drugs losing exclusivity, and Bureau of Labor Statistics methodology that swaps generics into the price index six months after brand patent expiration. She calls for consumer-facing apps that help patients shop hospital prices the same way they shop cars. Dr. Dawn covers the emerging science of dormant tumor cells—cancer cells that shed from primary tumors even before diagnosis, hide in bone marrow and lymph nodes, and enter a hibernation state (feeding off cellular residue via autophagy) that shields them from chemotherapy targeting rapidly dividing cells. New York researchers have identified proteins by which lung macrophages actively reinforce dormancy, but immune disruption from COVID-19, influenza, aging, and chronic stress can trigger reactivation. She emphasizes lifestyle protection for cancer survivors: minimal alcohol, Mediterranean diet, and five daily cups of green tea for the EGCG dormancy-maintaining effect seen in cell culture. A caller argues for single-payer healthcare and questions whether Medigap insurance is worth $287 monthly. Dr. Dawn explains the math: for a $100,000 hospital bill, 20% coinsurance is $20,000, making the $2,400 annual premium reasonable catastrophic-risk protection—though skipping it is a defensible bet for very low-utilization patients. She notes those whose income drops to Medi-Cal eligibility often end up with better coverage than middle-class seniors. The same caller then presents a differential diagnosis of himself as likely multiple sclerosis based on ChatGPT consultation, describing balance loss requiring hallway wall-guidance, dramatic vision changes, and fasciculations. Dr. Dawn walks through prompt engineering for medical AI: request differential lists ordered by probability of frequency in the population rather than symptom-fit alone. She notes symmetric symptoms argue against MS, suggests checking electrolytes (particularly calcium), and emphasizes that a physical examination should precede imaging to avoid incidentalomas that trigger cascading invasive workups—cautioning that without a primary care doctor, he lacks an advocate within the system.

Attend the 2026 Testicular Cancer Conference: https://www.testicularcancerawarenessfoundation.org/tcc-indianapolis-2026At just 24, personal trainer Andrejs Lejietis was building a business and living what he thought was a healthy, active life in Stockholm, Sweden — until a strange abdominal pain that kept returning after lunch led to one of the most confusing diagnoses in testicular cancer. In this episode of It Takes Balls, our first-ever Swedish guest shares a remarkable story about an extragonadal germ cell tumor: testicular cancer with no primary tumor in the testicles at all.Andrejs describes months of uncertainty as recurring pain near his aorta sent him from ultrasound to CT scan to a bone marrow biopsy, with doctors ruling out lymphoma before finally landing on a testicular cancer diagnosis. Encouraged by his girlfriend Emily to stop putting it off, he learned the value of self-advocacy the hard way — and discovered that a "good cancer to have" still hits hard when you're 24 with corporate clients lined up and a future you'd just started building.He opens up about four rounds of BEP chemotherapy at Karolinska University Hospital, an initial AFP tumor marker of 21,000, and stage 2C disease. Andrejs shares the realities of inpatient chemo, losing his hair, sperm banking and stem cell harvesting before treatment, and the unexpected gift of community — meeting other young men going through testicular cancer treatment at the same time.The conversation also covers his open RPLND (retroperitoneal lymph node dissection), a surgery Sweden has centralized to two hospitals for the best outcomes. Andrejs recounts a tumor wrapped around a vein near his left kidney, a difficult six-week recovery, neuropathy, retrograde ejaculation, and being discharged on Christmas Eve. Fourteen lymph nodes were removed — all clear.Andrejs and host Steven Crocker also dig into the Scandinavian healthcare system, where treatment, surgery, sperm banking, and even taxis to chemo are largely covered by taxes — and how testicular cancer, one of the most common cancers among young men, is treated across Europe.Now cancer-free and back to work, Andrejs reflects on how the journey reshaped his path toward becoming a physical therapist, the scar he wears with pride, and his advice for anyone newly diagnosed: take it one day at a time, stay as physically active as you can, and don't wait to get checked.Whether you're a testicular cancer patient, survivor, caregiver, or want to understand rare presentations like extragonadal germ cell tumors, Andrejs's story is a powerful reminder that early detection saves lives — and that you should never ignore symptoms that keep coming back.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyJoin The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here: https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsConnect with Andrejs:https://www.instagram.com/stepsforimprovementFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.x.com/testescancer⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker:https://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

In today's Beating Cancer Daily episode, Saranne explores creating a living legacy with excitement and optimism. As someone who has beaten Stage IV cancer for 30 years, Saranne shares her perspective on why it's essential to consciously think about and enjoy crafting a legacy, regardless of the timeline we have. Join her as she discusses fun and creative ways to leave a lasting imprint, from recording books for loved ones to planting living markers of our time. Get ready to be inspired and discover how embracing the concept of legacy can bring joy and depth to our lives as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

The Nurses Report on America Out Loud with Ashley Caputo, RN, FMP – We explore the remaining Terrain Ten factors, examining immune regulation, inflammation, circulation, hormones, biorhythms, stress, and emotional health while showing how interconnected systems shape whole-person cancer support, resilience, patient advocacy, and informed healthcare decisions beyond focusing solely on the tumor itself...

The Nurses Report on America Out Loud with Ashley Caputo, RN, FMP – We explore the remaining Terrain Ten factors, examining immune regulation, inflammation, circulation, hormones, biorhythms, stress, and emotional health while showing how interconnected systems shape whole-person cancer support, resilience, patient advocacy, and informed healthcare decisions beyond focusing solely on the tumor itself...

Warum alte Pflanzensorten die Ernährung sichern könnten ; Wie Transporte vom Fluss auf die Straße kommen ; Kann Virtual Reality die Klimakrise fühlbar machen? ; Große Fragen in zehn Minuten: Beeinflusst Sprache unser Handeln? ; So wichtig ist Feinmotorik für schulischen Erfolg von Kindern ; Mit Zellen gegen Nierenkrebs - Fortschritt in Krebsmedizin ; Moderation: Marija Bakker. Von WDR 5.

We love to hear from our listeners. Send us a message.In Episode 135 of Cell & Gene: The Podcast, Host Erin Harris talks to Sonal Gupta, MD, PhD, Chief Medical Officer of CoRegen, about the company's novel approach to treating solid tumors by engineering regulatory T cells (Tregs) rather than conventional effector immune cells. Dr. Gupta explains how CoRegen's investigational cell therapy, CRG150, targets the upstream regulator SRC3 to simultaneously influence multiple immune checkpoint pathways. She also discusses the scientific rationale behind the platform, the transition into first-in-human clinical studies, the biomarkers and translational questions the company hopes to answer, and why manufacturing, CDMO selection, and chain-of-identity capabilities are foundational to the future success of autologous cell therapies.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Colorectal cancer does not develop in isolation. Cancer cells exist within a complex tumor microenvironment made up of fibroblasts, immune cells, blood vessels, and extracellular matrix. Increasing evidence suggests that these surrounding cells and structures can influence whether tumors grow, regress, or evade the immune system. A research paper published in Volume 17 of Oncotarget, titled “Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer,” investigated the role of collagen triple helix repeat containing 1 (CTHRC1), a secreted protein found in cancer-associated stroma. Full blog post - https://www.oncotarget.org/2026/08/10/cthrc1-in-the-tumor-microenvironment-drives-colorectal-cancer-growth-in-mouse-study/ DOI - https://doi.org/10.18632/oncotarget.28878 Correspondence to: Sergey Ryzhov - Sergey.Ryzhov@mainehealth.org; Volkhard Lindner- Volkhard.Lindner@mainehealth.org; Michaela R. Reagan - Michaela.Reagan@mainehealth.org Abstract video - https://www.youtube.com/watch?v=gTbYy6vGd7E Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28878 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Cthrc1, CRC, colorectal cancer, subcutaneous tumor model, immune analysis To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Tumor shrinkage, long-term remissions, and radical recoveries—these stories reveal the real-world power of the Nutritarian diet. #CancerReversal #NutritarianSuccess #HealingStories #HealthTalks

This episode is sponosored by Hulu. Stream PRISON BREAK on Hulu in the U.S. and Disney+ Internationally. Sarah Wayne Callies and Paul Adelstein compare this episodes' stealthy Scylla-heist set pieces to Entrapment and Mission: Impossible, including trivia that the Mission: Impossible theme rhythm spells “M-I” in Morse code. They praise director Kevin Hooks' dynamic camera movement and staging, note the episode's original airdate (Nov. 17, 2008) and 5.5 million live viewers, and touch on 2008 music news (AC/DC's Black Ice; CMA and AMA winners). Their deeper conversation focuses on Michael's worsening brain tumor and the confusing logic of him avoiding the hospital while still doing intense physical work, plus “honeypot” seduction tactics failing for Gretchen (and earlier for Sara) but working better as a long con for Trishanne, leading into thoughts on Gretchen's trauma bond with the General. They also discuss gamma knife surgery, speculate whether the tumor storyline functioned as a possible behind-the-scenes “exit ramp” for Michael/Wentworth Miller while still serving the drama, and answer fan questions about Sara's evolving bond with Lincoln and whether Michael's refusal of surgery hurts Sara or reflects his stubborn hero complex. For the full experience of enjoying Prison Breaking With Sarah & Paul, subscribe to our Patreon channel where you can watch Sarah & Paul's running commentary on Ep 306 while re-watching the episode on Hulu or your home DVD collection. You can also watch in a group with other fans on our fan-led Discord server. Subscribe here: ⁠⁠⁠⁠https://patreon.com/user?u=116411884⁠⁠⁠⁠ -or- Click Link in Bio Patreon Subscribers get access to all of our Watch Parties and FanFiction (all captioned in six languages - English, French, Spanish, German, Portuguese, and Turkish), exclusive Ask Me Anything's with Sarah & Paul, and unannounced Discord drop-ins on our always rollicking server with fans and friends who come together from around the world. All for less than a cup of coffee. Leave us your comments, shoot us an email, or leave us a voicemail - we love hearing from all of you! prisonbreaking@caliber-studio.com (401) 3-PBREAK Watch the episode on YouTube - / @prisonbreakpodcast Follow us on Instagram - / prisonbreakpodcast Follow us on TikTok - / prisonbreakpodcast Merch!!! - https://pbmerch.printify.me/products #fyp #michaelscofield #saratancredi #michealscofield #prisonbreakedits #prisonbreak #wentworthmilleredits #wentworthmiller #editor #fyy #fyppp #saratancrediedit #prisonbreakseason1 #sarahwaynecallies #prisonbreakseason2 #scofield #fy #sarascofield #saratancrediedits #scofield Logo design by John Nunziatto @ Little Big Brands. If you want one yourself, reach out at https://www.littlebigbrands.com/ and tell him we sent you. PRISON BREAKING WITH SARAH & PAUL is a Caliber Studio production. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, Saranne delves into the world of tumor humor as she reflects on her experience with hair loss during her cancer journey. As a survivor, Saranne understands the emotional impact of losing hair during cancer treatment and shares how she approached this challenging experience with a comic perspective. Join her as she discusses the humorous side of coping with hair loss and invites listeners to participate in creating their tumor humor. Prepare for a lighthearted and insightful discussion on finding laughter in the face of adversity as we beat cancer daily together.2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Brain cancers are rare, but devastating. Patients face short life expectancies after diagnosis. Brain tumors are often impossible to remove completely. And radiation and chemotherapy don't always stop them from spreading.  It's a daunting class of disease to study, but that didn't dissuade Michelle Monje from trying. She has spent two decades studying how brain tumors form and interact with healthy brain cells, and pioneered the field of cancer neuroscience.  Guest: Dr. Michelle Monje is a professor of pediatric neuro-oncology at Stanford Medicine.  Other episodes you may enjoy: Promising new treatments for pancreatic cancer and ALS The new frontier of cancer research is in space Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today on Beating Cancer Daily, Saranne, the founder of the ComedyCures Foundation and a Stage IV cancer survivor for over 30 years, brings a much-needed lighthearted perspective to the realities of life with cancer. Through her signature humor and wisdom, she shares a laugh-out-loud colonoscopy joke and introduces listeners to the 31-Day Tumor Humor Challenge, designed to help reframe stressful cancer experiences. Saranne also discusses an inspiring Etsy poster that lists things we simply cannot control, encouraging listeners to identify and release these burdens, thereby finding greater healing and joy. With personal anecdotes about the controversial yet deeply meaningful decisions she made throughout her cancer journey, Saranne reminds everyone that humor and self-reflection go a long way in cultivating resilience on the toughest days.“My colonoscopy just confirmed that I'm beautiful inside and out.” ~Saranne2025 People's Choice Podcast Awards Best Health Series FinalistRanked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025,and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 to 2025. Beating Cancer Daily is listened to in 148 countries across 7 continents and features over 420+ original daily episodes hosted by Stage IV survivor Saranne Rothberg. To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne

Circulating tumor DNA (ctDNA), a minimally invasive blood-based biomarker, has emerged as one of the most promising advances in cancer surveillance. Today, we will explore how ctDNA is transforming the management of colorectal cancer and anal squamous cell cancer across the disease continuum—from risk stratification and adjuvant therapy decision-making to surveillance and early detection of recurrence. Through landmark clinical trials, real-world applications, and emerging research, we will examine how ctDNA is helping move cancer care closer to the goal of truly personalized medicine.Hosts: ·       Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center·       Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian·       Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital·       Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer CenterGuests:Dr. Paul Romessor ·      Director of Colorectal and Anal Cancer, Department of Radiation Oncology·      Associate Attending Radiation OncologistMemorial Sloan Kettering Cancer CenterDr. Jeanne Tie ·      Medical Oncologist | Lower GI Unit ·      Lower GI Research Lead ·      Chair | Lower GI Working Party | GI Cancer TrialsPeter MacCallum Cancer Centre Dr. Takayuki Yoshino·      Professor, Global Center of Research Excellence for Advanced Medicine (G-CORE),Keio University School of Medicine·      Executive Advisor to Hospital East Director·      Director, Department of Global Oncology·      Chief, Department of Gastrointestinal OncologyNational Cancer Center Hospital EastLearning Objectives:·      Describe the biological basis and clinical applications of circulating tumor DNA (ctDNA) as a biomarker of minimal residual disease (MRD) in colorectal cancer.·      Interpret the prognostic significance of postoperative and longitudinal ctDNA testing and its role in predicting recurrence risk across stages of colorectal cancer.·      Evaluate evidence from landmark clinical trials, including DYNAMIC and GALAXY, supporting ctDNA-guided treatment de-escalation and escalation strategies in colorectal cancer.·      Discuss emerging applications of ctDNA monitoring in personalized cancer care, including surveillance, treatment response assessment, and future clinical trial directions. References:·      Ando, K. et al. (2026). Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study. Annals of Surgery. https://pubmed.ncbi.nlm.nih.gov/39854721/ (Note: If direct access is limited, the article is available via PMC: PMC12695342)·      Romesser, P. B. et al. (2026). Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38347209/·      Tie, J. et al. (2025). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39943485/·      Tie, J. et al. (2025). Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/39974258/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Highlights from the PER® CME activity "Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Aunque tiene 70 años de carrera y desde hace dos necesita un doble trasplante de pulmón, Jorge Ortiz de Pinedo se mantiene activo en el medio artístico donde debutó a los ocho años, a instancias de sus padres Don Oscar Ortiz de Pinedo y de su madre Lupita Pallás.

Rebecca's story is one of extraordinary resilience. What began as a routine induction quickly turned into a life-threatening postpartum emergency, followed by the discovery of a rare orbital tumor, multiple surgeries, and a long road through PTSD and healing. In this heartfelt Listener Series episode, Rebecca shares how community, therapy, faith, and giving back helped her reclaim her life after birth trauma. If you've ever felt like your trauma became your identity, this conversation offers hope that healing is possible, even if it takes time.In this episode, we discuss:✨ Rebecca's difficult second pregnancy and the unexpected vision changes that led to the discovery of an orbital tumor

When we talk about EMF and cancer, the conversation usually focuses on risk. But what if electromagnetic fields could actually help treat cancer? In this episode, I break down a fascinating new study showing how pulsed electromagnetic field therapy altered the genetic profile of bladder cancer cells in the lab -- and what this tells us about the complex relationship between EMF and human biology. This isn't about fear. It's about understanding how the same technology that requires caution in one context might offer therapeutic benefits in another. In This Episode How pulsed electromagnetic fields changed gene expression in bladder cancer cells Why the same technology that poses risks can also treat disease What FDA-approved cancer treatments already use electromagnetic fields The key difference between therapeutic EMF and everyday exposure Featured Study Read the full study: Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer Cell Line HT-1197 See all studies at shieldyourbody.com/research

Host: Darryl S. Chutka, M.D.  Guests: Jake Eide, M.D. & Rijul Kshirsager, M.D.  Skull base tumors are not commonly seen in a primary care practice, yet it's important for us to recognize them when they do present. These tumors can be either benign or malignant, however because of their proximity to important structures in the brain, even benign tumors can cause serious complications. Their presentation can be subtle, and they are frequently mistaken for other more commonly seen health problems. Which presenting symptoms should give us concern? What are some common physical exam findings associated with these tumors, and what's the best initial imaging study to order? These are some of the questions I'll be asking my guests, Dr. Jake Eide and Dr. Rijul Kshirsagar, both surgeons in the Department of Otorhinolaryngology at the Mayo Clinic as we tackle “Skull Base Tumors.”  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Glioblastoma is considered one of the most aggressive brain cancers, with survival often limited to about a year, largely because tumors adapt by rewiring how they use nutrients and energy Tumors divert vitamin B3 (niacinamide) away from normal energy production into a pathway that supports their survival, suggesting a metabolic weakness that could potentially be targeted This altered pathway may drain key cellular resources, meaning cancer cells appear to burn through materials they need to grow, which may create an opportunity to disrupt their fuel supply In a Science Advances study, high-dose vitamin B3 therapy was associated with improved short-term outcomes in patients, with over 80% showing no disease progression at six months in early findings, along with stronger immune activity against tumors Supporting your body's energy production and immune response through diet, lifestyle, and structured nutrient intake may help influence the same metabolic systems cancer depends on

Immune discusses a snippet on how EBV infection alters the immunopeptidome and promotes multiple sclerosis, and a paper on head and neck cancers harboring bacteria that create an immunosuppressive environment and promote immunotherapy resistance. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server EBV, Golli-MBP presentation and multiple sclerosis (Cell, 2026) Intratumoral bacteria promote resistance to cancer immunotherapy (Nat Cancer, 2026) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.